Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Dedelow

Obstetrics & Gynecology Hobart, IN Doctor of Osteopathy

NPI 1861492993 CMS profile 39223

1400 S Lake Park Ave, Ste 205, Hobart, IN 46342

Open in the dashboard

General payments

$15,902

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Douglas Dedelow of Hobart, IN is reported in the CMS Open Payments database as having received $15,902 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $818 30
2024 General $388 17
2023 General $592 28
2022 General $2,447 34
2021 General $924 49
2020 General $1,960 38
2019 General $8,771 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Dedelow
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Douglas Dedelow were reported at $818. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Douglas Dedelow Obstetrics & Gynecology median Middle half National median
2019 $8,771 $172 $62–$391 $163
2020 $1,960 $94 $36–$222 $114
2021 $924 $136 $42–$369 $132
2022 $2,447 $160 $50–$433 $149
2023 $592 $169 $56–$423 $160
2024 $388 $152 $50–$371 $164
2025 $818 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acessa Health Inc. $7,102 11 payments
  2. Stryker Corporation $1,901 7 payments
  3. Coloplast Corp $1,670 16 payments
  4. AbbVie, Inc. $995 66 payments
  5. Intuitive Surgical, Inc. $917 5 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $236 11 payments
  7. Agile Therapeutics, Inc. $208 9 payments
  8. Exeltis, USA Inc. $193 10 payments
  9. Avion Pharmaceuticals $188 11 payments
  10. Pfizer Inc. $183 9 payments
  11. Other $2,310 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,500 12 payments
  2. Food and Beverage $5,185 239 payments
  3. Consulting Fee $5,000 3 payments
  4. Education $216 11 payments
Products named General payments · program years 2019–2025
  1. Acessa $7,102 11 payments
  2. SPY-PHI SYSTEM $1,472 3 payments
  3. AXIS $1,131 5 payments
  4. Da Vinci Surgical System $917 5 payments
  5. LO LOESTRIN FE $504 26 payments
  6. IRIS $428 4 payments
  7. ALTIS $331 2 payments
  8. ORILISSA Womens Health $257 17 payments
  9. MYFEMBREE $257 12 payments
  10. Orilissa Endocrinology $246 22 payments
  11. Other $4,243 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

242

Median for Obstetrics & Gynecology: 65

Drug cost

$4,263

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

29.3%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 26 $1,773
Metronidazole Generic 30 $1,000
Acyclovir Generic 12 $537
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 27 $295
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 13 $290
Fluconazole Generic 51 $157
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $61
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $56
Alendronate Sodium Generic 20 $43
Tramadol Hcl Generic 20 $36

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$28,378

Medicare's payments for the services billed

Medicare patients

99

Average age 70

Services billed

256

99 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 33%
Depression 26%
Ischemic heart disease 23%
Osteoporosis 18%
Chronic kidney disease 16%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $50
  • PFIZER INC. $21
$71 — —
SLYND
  • Exeltis, USA Inc. $61
$61 — —
Mirena
  • Bayer HealthCare Pharmaceuticals Inc. $36
$36 — —
PREMARIN
  • PFIZER INC. $21
$21 — —
DUAVEE
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record